DNMT1 and myelodysplastic syndrome: To date, only two FDA-approved drugs (azacytidine and decitabine) are available that target DNMT1 in addition to other DNMTs for the treatment of myelodysplastic syndrome (Gnyszka, Jastrzębski, and Flis 2013).